K Rossing, KJ Schjoedt, UM Smidt, F … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—During the addition of placebo, values were as follows: albuminuria
(geometric mean [range]) 1,566 [655–7,762] mg/24 h, ABP (mean ± SE) 138 ±
3/71 ± 1 mmHg, and GFR (mean ± SE) 74 ± 6 ml/min per 1.73 m 2 . During ... Cited by 88 - Related articles - BL Direct - All 5 versions
KJ Schjoedt, K Rossing, TR Juhl, F Boomsma, … - Kidney international, 2005 - nature.com Aldosterone has been suggested to play a role in the initiation and progression
of diabetic nephropathy. Currently recommended treatment with
angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor ... Cited by 75 - Related articles - BL Direct - All 5 versions
R Rachmani, I Slavachevsky, M Amit, Z Levi, … - Diabetic medicine, 2004 - interscience.wiley.com Patients and methods Sixty female diabetic patients aged 45–70 years with
blood pressure (BP) 140–180/90–110 mmHg, serum creatinine (sCr) ≤ 160
µmol/l, HbA 1c ≤ 10%, and albuminuria were treated by atenolol 12.5–75 ... Cited by 87 - Related articles - BL Direct - All 5 versions
KJ Schjoedt, K Rossing, TR Juhl, F Boomsma, … - Kidney international, 2006 - nature.com Reduction of nephrotic range albuminuria is associated with markedly improved
renal and cardiovascular outcome in patients with diabetic nephropathy.
Aldosterone has been suggested to play a role in the progression of ... Cited by 63 - Related articles - BL Direct - All 4 versions
- ►asnjournals.org M Epstein, GH Williams, M Weinberger, A … - Clinical Journal of the American Society of Nephrology, 2006 - Am Soc Nephrol Previous studies have shown that the selective aldosterone blocker eplerenone,
in doses of up to 200 mg/d, reduces albuminuria in patients with type 2
diabetes. This study was conducted to ascertain whether lower doses of ... Cited by 81 - Related articles - BL Direct - All 3 versions
S Bianchi, R Bigazzi, VM Campese - American Journal of Kidney Diseases, 2005 - Elsevier Background: Experimental evidence suggests that aldosterone may contribute to
progressive kidney disease. Although angiotensin-converting enzyme (ACE)
inhibitors and angiotensin type 1 receptor antagonists (ARBs) suppress the ... Cited by 68 - Related articles - All 5 versions
- ►asnjournals.org A Chrysostomou, E Pedagogos, L MacGregor, … - Clinical Journal of the American Society of Nephrology, 2006 - Am Soc Nephrol Studies have shown that dual therapy with angiotensin-converting enzyme
inhibitors (ACEI) and either angiotensin II receptor blockers or aldosterone
receptor antagonists is more effective in reducing proteinuria than either ... Cited by 63 - Related articles - BL Direct - All 3 versions
A Sato, K Hayashi, T Saruta - American journal of hypertension, 2005 - Elsevier We have recently shown that mineralocorticoid receptor blockade may represent
optimal therapy for patients with early diabetic nephropathy who show
aldosterone breakthrough during angiotensin-converting enzyme (ACE) ... Cited by 71 - Related articles - All 4 versions
- ►ahajournals.org A Sato, K Hayashi, M Naruse, T Saruta - Hypertension, 2003 - Am Heart Assoc It has been reported that continuous ACE inhibitor therapy does not necessarily
produce a maintained decrease in plasma aldosterone levels, which may remain
high or increase eventually during long-term use (aldosterone escape). We ... Cited by 235 - Related articles - BL Direct - All 7 versions
